Drugs / imexon
imexon
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00327223 | Nov 2005 → Sep 2006 | metastatic neoplasm | AmpliMed Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00327288 | Oct 2005 → Jul 2008 | breast cancer, non-small cell lung carcinoma, prostate cancer | AmpliMed Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00327327 | Feb 2004 → Oct 2009 | pancreatic adenocarcinoma | AmpliMed Corporation | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00327249 | Oct 2005 → Jul 2006 | plasma cell myeloma | AmpliMed Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00327600 | Jul 2005 → Jan 2007 | melanoma | AmpliMed Corporation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01314014 | May 2011 → Mar 2013 | Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +3 | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00697060 | Aug 2010 → Aug 2011 | non-small cell lung carcinoma | AmpliMed Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT00637247 | Apr 2008 → May 2010 | pancreatic neoplasm | AmpliMed Corporation | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imexon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697060 ↗ |
| Known as | Amplimexon | “BACKGROUND: Imexon (Amplimexon) is an aziridine compound that increases reactive oxygen species, disrupts mitochondrial membranes, and induces apoptosis.” PMID 20564083 ↗ Aug 20103“A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy” NCT00327223 ↗ “A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma” NCT00327327 ↗ “A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma” NCT00327249 ↗ |
| Known as | Amplimexon (imexon for injection) | “Amplimexon (imexon for injection)” NCT01314014 ↗ |
| Known as | NSC-313425 | ChEMBL registry synonym — accepted as the source's own label CHEMBL146428 ↗ |
| Known as | NSC-714597 | “We therefore designed a phase 2 study of imexon (Amplimexon/NSC-714597), a prooxidant molecule, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).” PMID 25016003 ↗ Jul 2014 |
| Modality | Small molecule | “Imexon is an iminopyrrolidone that induces apoptosis and has synergistic activity with docetaxel in preclinical models.” PMID 19499186 ↗ Jun 2009 |
| Route | Intravenous | “26 patients received escalating doses of imexon given intravenously over 60 min on days 1-5 every 21 days.” PMID 19499186 ↗ Jun 2009 |